MCID: CLR109
MIFTS: 51

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 15 17
Adenocarcinoma of Large Intestine 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
NCIt 49 C5105
SNOMED-CT 67 408645001
UMLS 71 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to colorectal adenoma and adenocarcinoma. An important gene associated with Colorectal Adenocarcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Iron and Hepcidins have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 576)
# Related Disease Score Top Affiliating Genes
1 colorectal adenoma 32.9 VEGFA TP53 MLH1 KRAS HRAS EGFR
2 adenocarcinoma 31.8 VEGFA TP53 MLH1 KRT7 KRT20 KRAS
3 adenoma 31.4 TP53 MLH1 KRT7 KRT20 KRAS CTNNB1
4 rectum cancer 31.4 MLH1 KRT20 KRAS HRAS CEACAM5
5 appendix adenocarcinoma 31.3 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
6 familial adenomatous polyposis 31.2 TP53 MLH1 KRAS HRAS CTNNB1 CDH1
7 bladder adenocarcinoma 31.1 KRT7 KRT20 CTNNB1 CDX2
8 gastrointestinal stromal tumor 31.0 VEGFA TP53 KRAS EGFR CDH1 BRAF
9 colon adenocarcinoma 31.0 VEGFA TP53 MLH1 KRT20 KRAS EGFR
10 lynch syndrome 31.0 TP53 MLH1 KRAS HRAS EGFR CTNNB1
11 mucinous adenocarcinoma 31.0 VEGFA TP53 MLH1 KRT7 KRT20 KRAS
12 exanthem 30.9 VEGFA KRAS HRAS EGFR
13 small intestine adenocarcinoma 30.8 MLH1 KRAS CTNNB1 CDX2
14 rectum adenocarcinoma 30.7 TP53 MLH1 KRT7 KRT20 KRAS HRAS
15 urachal adenocarcinoma 30.7 KRAS CEACAM5 BRAF
16 familial colorectal cancer 30.7 MLH1 CDH1 BRAF
17 thyroid carcinoma 30.7 HRAS CDH1 BRAF
18 mucinous bronchioloalveolar adenocarcinoma 30.7 KRT7 KRT20 CDX2
19 villous adenoma 30.7 TP53 MLH1 KRT20 KRAS HRAS CEACAM5
20 lymphoma 30.6 TP53 PIM2 EGFR CDH1 BRAF ATM
21 goblet cell carcinoid 30.6 KRT20 CTNNB1 CDH1
22 lymphoepithelioma-like carcinoma 30.6 KRT7 KRT20 CDH1
23 cystitis cystica 30.6 KRT7 KRT20 CEACAM5 CDX2
24 hepatoid adenocarcinoma 30.6 KRT7 EGFR CEACAM5 CDX2
25 colorectal cancer 30.5 VEGFA TP53 MLH1 MIR182 KRT7 KRT20
26 neuroendocrine carcinoma 30.5 KRT7 KRT20 CEACAM5 CDH1
27 intrahepatic cholangiocarcinoma 30.5 TP53 KRT7 KRT20 KRAS EGFR CTNNB1
28 embryonal rhabdomyosarcoma 30.5 TP53 KRAS HRAS
29 pleomorphic adenoma 30.5 TP53 KRT7 HRAS CTNNB1
30 rhabdomyosarcoma 30.5 VEGFA TP53 KRAS HRAS EGFR CTNNB1
31 intestinal obstruction 30.4 VEGFA KRT7 KRT20 CEACAM5 CDX2
32 esophagitis 30.4 VEGFA TP53 EGFR
33 in situ carcinoma 30.4 TP53 HRAS EGFR CTNNB1 CDH1
34 mesothelioma, malignant 30.4 KRT7 KRT20 CTNNB1 CEACAM5 CDH1
35 cystitis 30.4 VEGFA TP53 KRT7 KRT20 CDX2 CDH1
36 neurofibromatosis, type ii 30.4 VEGFA TP53 HRAS EGFR CTNNB1
37 neuroendocrine tumor 30.4 VEGFA KRT20 HRAS CDX2 CDH1
38 cystadenocarcinoma 30.4 VEGFA TP53 KRT7 HRAS CEACAM5 BRAF
39 sarcoma 30.4 VEGFA TP53 KRAS HRAS CTNNB1 BRAF
40 colon adenoma 30.3 VEGFA MIR182 KRAS
41 chordoma 30.3 VEGFA TP53 KRT7 EGFR CTNNB1 CDH1
42 breast ductal carcinoma 30.3 VEGFA TP53 KRT7 EGFR CTNNB1 CDH1
43 cowden syndrome 30.3 TP53 MLH1 HRAS EGFR CTNNB1 ATM
44 pancreatic ductal adenocarcinoma 30.3 VEGFA TP53 KRAS EGFR CTNNB1 CDH1
45 cholangiocarcinoma 30.3 TP53 KRT7 KRT20 KRAS EGFR CTNNB1
46 neuroblastoma 30.3 VEGFA TP53 HRAS EGFR CTNNB1 CDH1
47 bronchiolo-alveolar adenocarcinoma 30.3 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
48 oral squamous cell carcinoma 30.2 VEGFA TP53 HRAS EGFR CTNNB1 CDH1
49 retinitis pigmentosa 11 30.2 TP53 HRAS EGFR
50 tubular adenocarcinoma 30.2 KRT7 KRT20 EGFR CTNNB1 CEACAM5 CDX2

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.96 AURKA BRAF EGFR KRAS PIM2 HRAS
2 Decreased viability GR00055-A-2 10.96 AURKA BRAF EGFR KRAS PIM2 HRAS
3 Decreased viability GR00055-A-3 10.96 KRAS
4 Decreased viability GR00106-A-0 10.96 KRAS
5 Decreased viability GR00173-A 10.96 CDK8
6 Decreased viability GR00221-A-1 10.96 AURKA CDK8 EGFR CDH1 KRAS PIM2
7 Decreased viability GR00221-A-2 10.96 AURKA CDK8 KRAS HRAS
8 Decreased viability GR00221-A-3 10.96 ATM HRAS
9 Decreased viability GR00221-A-4 10.96 ATM AURKA BRAF CDK8 EGFR
10 Decreased viability GR00231-A 10.96 AURKA
11 Decreased viability GR00249-S 10.96 AURKA BRAF
12 Decreased viability GR00301-A 10.96 BRAF CDK8 CDH1 KRAS PIM2
13 Decreased viability GR00381-A-1 10.96 BRAF KRAS
14 Decreased viability GR00402-S-2 10.96 AURKA CDH1 PIM2
15 Decreased cell migration GR00055-A-1 10.06 ATM
16 Decreased cell migration GR00055-A-3 10.06 AURKA BRAF EGFR HRAS
17 Decreased cell–culture–derived Hepatitis C virus (HCVcc; Luc–Jc1) infection GR00234-A-2 9.67 ATM BRAF CDK8 EGFR
18 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.62 ATM BRAF CDK8 EGFR
19 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.26 ATM BRAF
20 Reduced mammosphere formation GR00396-S 9.17 ATM BRAF CDH1 EGFR HRAS KRAS
21 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 ATM AURKA BRAF CDH1 CDX2 CTNNB1
2 cardiovascular system MP:0005385 10.31 ATM BRAF CDH1 CDK8 CDX2 CTNNB1
3 growth/size/body region MP:0005378 10.31 ATM AURKA BRAF CDH1 CDK8 CDX2
4 homeostasis/metabolism MP:0005376 10.29 ATM BRAF CDH1 CDX2 CTNNB1 EGFR
5 embryo MP:0005380 10.26 ATM AURKA BRAF CDH1 CDK8 CDX2
6 endocrine/exocrine gland MP:0005379 10.25 ATM BRAF CDH1 CDX2 CTNNB1 EGFR
7 mortality/aging MP:0010768 10.25 ATM AURKA BRAF CDH1 CDK8 CDX2
8 digestive/alimentary MP:0005381 10.24 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
9 integument MP:0010771 10.16 ATM BRAF CDH1 CTNNB1 EGFR HRAS
10 neoplasm MP:0002006 10.15 ATM AURKA BRAF CDH1 CDX2 CTNNB1
11 craniofacial MP:0005382 10.09 BRAF CTNNB1 EGFR HRAS KRAS TP53
12 limbs/digits/tail MP:0005371 9.98 BRAF CDX2 CTNNB1 EGFR KRAS TP53
13 no phenotypic analysis MP:0003012 9.92 AURKA CDH1 CTNNB1 EGFR HRAS KRAS
14 normal MP:0002873 9.91 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
15 renal/urinary system MP:0005367 9.76 BRAF CTNNB1 EGFR HRAS KRAS KRT7
16 reproductive system MP:0005389 9.65 ATM BRAF CDH1 CDX2 CTNNB1 EGFR
17 respiratory system MP:0005388 9.23 BRAF CTNNB1 EGFR HRAS KRAS MLH1

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
2 Hepcidins Phase 4
3 Iron Supplement Phase 4
4
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
7
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
8
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
9
Nicotine Approved Phase 3 54-11-5 942 89594
10
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
11
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
12
Fluorouracil Approved Phase 3 51-21-8 3385
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
15
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
16
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
20 topoisomerase I inhibitors Phase 3
21 Pharmaceutical Solutions Phase 3
22 Anti-Bacterial Agents Phase 3
23 Alkylating Agents Phase 3
24
Liposomal doxorubicin Phase 3 31703
25 Antibiotics, Antitubercular Phase 3
26 Calciferol Phase 3
27 Mitomycins Phase 2, Phase 3
28 Angiogenesis Inhibitors Phase 3
29 Immunoglobulin G Phase 3
30 Antimetabolites Phase 3
31 Vitamins Phase 3
32 Immunologic Factors Phase 3
33 Micronutrients Phase 3
34 Antidotes Phase 3
35 Vitamin B Complex Phase 3
36 Folate Phase 3
37 Immunosuppressive Agents Phase 3
38 Nutrients Phase 3
39 Trace Elements Phase 3
40 Vitamin B9 Phase 3
41 Protective Agents Phase 3
42 Antineoplastic Agents, Immunological Phase 3
43 Immunoglobulins Phase 3
44 Antibodies Phase 3
45 Antibodies, Monoclonal Phase 3
46 Hematinics Phase 3
47 Hormones Phase 3
48 Calcium, Dietary Phase 3
49 Immunoglobulins, Intravenous Phase 3
50 Formyltetrahydrofolates Phase 3

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
2 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
3 Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases Completed NCT01972490 Phase 4 avastin;mFOLFOX6
4 An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
5 A Multicenter,Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma Unknown status NCT02390947 Phase 3 Famitinib;Placebo
6 Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
7 A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN) Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
8 A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
9 A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
10 Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
11 The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial Completed NCT00265356 Phase 3
12 A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum Completed NCT00023868 Phase 3 FOLFIRI regimen;cisplatin;doxorubicin hydrochloride;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C
13 A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
14 Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05 Completed NCT00126256 Phase 3 5-fluorouracil;leucovorin;irinotecan;oxaliplatin
15 A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
16 Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS) Recruiting NCT04094688 Phase 3 Bevacizumab;Oxaliplatin;Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Irinotecan
17 Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study Recruiting NCT02758951 Phase 2, Phase 3
18 TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy Active, not recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
19 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial Not yet recruiting NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
20 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Suspended NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin;Oxaliplatin
21 Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab Terminated NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
22 A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
23 Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
24 Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70 Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
25 Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer Unknown status NCT00075556 Phase 2 capecitabine
26 A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
27 Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
28 Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI Unknown status NCT01858649 Phase 2 Bevacizumab;5 FU;Oxaliplatin;Irinotecan
29 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
30 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma . Completed NCT02788006 Phase 2 Regorafenib 160 mg
31 Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
32 A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
33 A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens Completed NCT00419159 Phase 2 Everolimus (RAD001)
34 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
35 Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
36 A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma Completed NCT00025350 Phase 2 gefitinib
37 Regorafenib Assessment in Refractory Advanced Colorectal Cancer Completed NCT01929616 Phase 2 regorafenib
38 A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859) Completed NCT00574171 Phase 2 lapatinib;Capecitabine
39 A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
40 An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma Completed NCT01053013 Phase 2
41 A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy Completed NCT00030524 Phase 2 gefitinib
42 Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease Completed NCT00890305 Phase 2 CT-011;FOLFOX
43 A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II) Completed NCT00025142 Phase 2 FOLFOX regimen;fluorouracil;gefitinib;leucovorin calcium;oxaliplatin
44 Randomised Controlled Trial of the Effects of Fish Oil Emulsion in Total Parenteral Nutrition Upon Tumour Vascularity in Patients With Hepatic Colorectal Metastases Completed NCT00942292 Phase 2
45 A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum Completed NCT00080834 Phase 2 DJ-927
46 A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum Completed NCT00056030 Phase 2 fluorouracil;leucovorin calcium;oxaliplatin
47 A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer Completed NCT00531245 Phase 1, Phase 2 TS-1, oxaliplatin
48 A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
49 Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
50 A Randomized, Multicenter, Phase II Study Of Bolus/Infusion 5-FU/LV (de Gramont Regimen) Versus Oxaliplatin And Bolus/Infusion 5-FU/LV (de Gramont Regimen) As Third-Line Treatment Of Patients With Metastatic Colorectal Carcinoma Completed NCT00016198 Phase 2 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

40
Colon, Liver, Lymph Node, Lung, Testes, Endothelial, T Cells

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 3521)
# Title Authors PMID Year
1
Diallyl disulphide-loaded spherical gold nanoparticles and acorn-like silver nanoparticles synthesised using onion extract: catalytic activity and cytotoxicity. 61
32496831 2020
2
FOXA1-induced LINC01207 facilitates head and neck squamous cell carcinoma via up-regulation of TNRC6B. 61
32450521 2020
3
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines. 61
32311402 2020
4
Synthesis and evaluation of novel sulfonamide analogues of 6/7-aminoflavones as anticancer agents via topoisomerase II inhibition. 61
32527548 2020
5
Synthesis and biological evaluation of arylphosphonium-benzoxaborole conjugates as novel anticancer agents. 61
32527557 2020
6
Cupric Oxide Nanoparticles Induce Cellular Toxicity in Liver and Intestine Cell Lines. 61
32373489 2020
7
[Clinicopathological and molecular features of pulmonary enteric adenocarcinoma]. 61
32486530 2020
8
Increasing Yttrium-90 Dose Conformality Using Proximal Radioembolization Enabled by Distal Angiosomal Truncation for the Treatment of Hepatic Malignancy. 61
32381352 2020
9
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. 61
32520749 2020
10
Antioxidant, Anti-Inflammatory and Cytotoxicity Properties of Centaurea africanaLamk var. [Bonnet] M. 61
32516104 2020
11
Detection of the 'systemic sentinel lymph node' in colorectal cancer using fluorescence imaging after indocyanine green intravenous injection: A feasibility study. 61
32554370 2020
12
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. 61
32246441 2020
13
Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. 61
32166754 2020
14
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. 61
32495162 2020
15
Triterpenoid saponins from Calliandra calothyrsus Meisn. and their antiproliferative activity against two digestive carcinoma human cell lines. 61
32540379 2020
16
G9a Is SETting the Stage for Colorectal Oncogenesis. 61
32512705 2020
17
Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy. 61
32402303 2020
18
Positive correlation of expression of L-type amino-acid transporter 1 with colorectal tumor progression and prognosis: Higher expression in sporadic colorectal tumors compared with ulcerative colitis-associated neoplasia. 61
32359697 2020
19
Influence of Heterologously Expressed azurin from Pseudomonas aeruginosa on the Adhesion and Invasion of Pathogenic Bacteria to the Caco-2 Cell Line. 61
31364004 2020
20
Colorectal neuroendocrine tumors: A case series. 61
32563832 2020
21
About the impact of superassociation of hydrophobic ion pairs on membrane permeability. 61
32268189 2020
22
Correlation of Algorithmic and Visual Assessment of Lesion Detection in Clinical Images. 61
31447259 2020
23
Isolation and characterization of cytotoxic and insulin-releasing components from the venom of the black-necked spitting cobra Naja nigricollis (Elapidae). 61
32550585 2020
24
Immune Microenvironment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma and Liver Metastasis of Colorectal Adenocarcinoma: Relationship with Histopathological and Molecular Classifications. 61
32573056 2020
25
Serrated adenomas with a BRAF mutation in a young patient with familial adenomatous polyposis. 61
32504335 2020
26
PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer. 61
32548664 2020
27
Pathologic Factors Affecting Colorectal Cancer Survival in a Jamaican Population-the UHWI Experience. 61
31768964 2020
28
High MICB expression as a biomarker for good prognosis of colorectal cancer. 61
32306128 2020
29
Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. 61
32239529 2020
30
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. 61
32386571 2020
31
Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features. 61
32222462 2020
32
Ferrate(VI) pretreatment before disinfection: An effective approach to controlling unsaturated and aromatic halo-disinfection byproducts in chlorinated and chloraminated drinking waters. 61
32203804 2020
33
Functionalized Surface-Charged SiO2 Nanoparticles Induce Pro-Inflammatory Responses, but Are Not Lethal to Caco-2 Cells. 61
32319286 2020
34
The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. 61
32378087 2020
35
Correction: A qualitative transcriptional signature for determining the grade of colorectal adenocarcinoma. 61
31801988 2020
36
Molecular and clinicopathological features of colorectal adenocarcinoma with enteroblastic differentiation. 61
32438490 2020
37
Synthesis of combinatorial Janus nanoparticles based on EpCAM-PEG/PCL for targeted therapy of human colorectal adenocarcinoma. 61
32363740 2020
38
Tumor-to-Tumor Metastasis of Colorectal Adenocarcinoma to Ovarian Cystadenofibroma: A Case Report and Review of the Literature. 61
30882401 2020
39
DNA damage and DNA protection from digested raw and griddled green pepper (poly)phenols in human colorectal adenocarcinoma cells (HT-29). 61
32430553 2020
40
CDH1 gene mutation in early-onset, colorectal signet-ring cell carcinoma. 61
32147272 2020
41
Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling. 61
32004978 2020
42
[Incidental finding of leukocyte cell-derived chemotaxin 2 - Associated amyloidosis in a liver]. 61
32446730 2020
43
Cell and nucleus refractive-index mapping by interferometric phase microscopy and rapid confocal fluorescence microscopy. 61
32468735 2020
44
Characterization of colibactin-producing Escherichia coli isolated from Japanese patients with colorectal cancer. 61
32475872 2020
45
Exosomes Derived from the Human Primary Colorectal Cancer Cell Line SW480 Orchestrate Fibroblast-Led Cancer Invasion. 61
32438511 2020
46
Gastrointestinal involvement of primary skin diseases. 61
32455473 2020
47
Colorectal cancer and trace elements alteration. 61
31954212 2020
48
A twelve-year study of the prevalence, risk factors and characteristics of interval colorectal cancers after negative colonoscopy. 61
31302010 2020
49
Pure Discrete Punctate Nuclear Staining Pattern for MLH1 Protein Does Not Represent Intact Nuclear Expression. 61
31566049 2020
50
Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy. 61
32311417 2020

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 VEGFA TP53 KRAS HRAS EGFR CTNNB1
2
Show member pathways
13.52 VEGFA KRT7 KRT20 KRAS HRAS EGFR
3
Show member pathways
13.31 VEGFA KRAS HRAS EGFR CTNNB1 CDH1
4
Show member pathways
13.09 TP53 KRAS HRAS EGFR CTNNB1 BRAF
5
Show member pathways
13.07 VEGFA KRAS HRAS EGFR CTNNB1 BRAF
6
Show member pathways
13.01 VEGFA TP53 KRAS HRAS EGFR CTNNB1
7
Show member pathways
13.01 VEGFA TP53 KRAS HRAS CTNNB1 CDH1
8
Show member pathways
12.97 VEGFA TP53 KRAS HRAS EGFR CTNNB1
9
Show member pathways
12.94 VEGFA KRAS HRAS EGFR CTNNB1 BRAF
10 12.79 VEGFA TP53 KRAS HRAS EGFR BRAF
11
Show member pathways
12.77 VEGFA TP53 PIM2 MLH1 KRAS HRAS
12
Show member pathways
12.75 TP53 KRAS HRAS CTNNB1 CDH1 BRAF
13
Show member pathways
12.75 VEGFA KRAS HRAS EGFR CTNNB1 CDH1
14
Show member pathways
12.71 VEGFA KRT20 KRAS HRAS EGFR
15
Show member pathways
12.71 TP53 KRAS HRAS EGFR BRAF
16
Show member pathways
12.69 TP53 MLH1 KRAS HRAS EGFR CTNNB1
17
Show member pathways
12.68 TP53 KRAS HRAS EGFR CDH1 BRAF
18 12.68 VEGFA TP53 PIM2 MLH1 KRAS HRAS
19
Show member pathways
12.64 VEGFA TP53 KRAS HRAS EGFR BRAF
20
Show member pathways
12.63 TP53 KRAS HRAS EGFR CTNNB1
21 12.56 TP53 MLH1 CDK8 AURKA ATM
22 12.56 VEGFA TP53 KRAS HRAS EGFR ATM
23
Show member pathways
12.55 TP53 KRAS HRAS EGFR BRAF
24
Show member pathways
12.49 VEGFA TP53 KRAS HRAS EGFR CTNNB1
25
Show member pathways
12.47 TP53 KRAS HRAS EGFR CTNNB1 ATM
26
Show member pathways
12.43 KRAS HRAS EGFR CTNNB1 CDH1 BRAF
27
Show member pathways
12.43 VEGFA KRAS HRAS CTNNB1 BRAF
28 12.38 TP53 KRAS HRAS ATM
29
Show member pathways
12.35 TP53 HRAS EGFR CTNNB1
30
Show member pathways
12.32 KRAS HRAS EGFR CTNNB1 CDH1 BRAF
31
Show member pathways
12.31 KRAS HRAS FGFBP1 BRAF
32
Show member pathways
12.31 VEGFA TP53 KRAS HRAS EGFR BRAF
33
Show member pathways
12.28 TP53 KRAS HRAS EGFR BRAF
34 12.26 VEGFA TP53 KRAS HRAS EGFR CTNNB1
35
Show member pathways
12.22 TP53 KRAS HRAS BRAF
36 12.22 KRAS HRAS EGFR BRAF AURKA
37 12.2 TP53 KRAS HRAS ATM
38
Show member pathways
12.19 TP53 KRAS HRAS BRAF
39
Show member pathways
12.14 KRAS HRAS BRAF
40
Show member pathways
12.12 KRAS HRAS EGFR BRAF ATM
41
Show member pathways
12.11 TP53 KRAS HRAS EGFR ATM
42 12.07 KRAS HRAS CTNNB1 CDH1
43 12.06 TP53 KRAS HRAS CTNNB1
44 12.01 TP53 KRAS HRAS CTNNB1 ATM
45 11.98 TP53 KRAS HRAS EGFR CTNNB1 BRAF
46 11.98 VEGFA TP53 MLH1 KRAS EGFR CTNNB1
47
Show member pathways
11.84 KRAS HRAS BRAF
48 11.82 TP53 KRAS BRAF
49 11.78 TP53 MLH1 ATM
50 11.77 TP53 KRAS HRAS EGFR

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CTNNB1 CDH1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 VEGFA TP53 HRAS EGFR CTNNB1 CDK8
2 phosphorylation GO:0016310 10.04 PIM2 EGFR CDK8 BRAF AURKA ATM
3 apoptotic process GO:0006915 10.02 TP53 PIM2 KRT20 HRAS CEACAM5 ATM
4 positive regulation of transcription, DNA-templated GO:0045893 9.99 TP53 PIM2 EGFR CTNNB1 CDX2 CDH1
5 protein phosphorylation GO:0006468 9.95 PIM2 EGFR CDK8 BRAF AURKA ATM
6 regulation of cell proliferation GO:0042127 9.93 TP53 EGFR CTNNB1 BRAF
7 positive regulation of protein phosphorylation GO:0001934 9.89 VEGFA KRAS HRAS EGFR
8 negative regulation of gene expression GO:0010629 9.85 VEGFA TP53 HRAS CTNNB1 AURKA
9 negative regulation of cell proliferation GO:0008285 9.85 TP53 PIM2 HRAS FGFBP1 FABP6 CTNNB1
10 protein autophosphorylation GO:0046777 9.84 PIM2 EGFR AURKA ATM
11 Ras protein signal transduction GO:0007265 9.82 TP53 KRAS HRAS
12 cellular response to drug GO:0035690 9.8 TP53 EGFR BRAF
13 positive regulation of cell migration GO:0030335 9.8 VEGFA MIR182 HRAS EGFR ATM
14 positive regulation of epithelial cell proliferation GO:0050679 9.78 VEGFA HRAS EGFR
15 positive regulation of neuron apoptotic process GO:0043525 9.76 TP53 CTNNB1 ATM
16 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.75 TP53 AURKA ATM
17 positive regulation of cell proliferation GO:0008284 9.7 VEGFA KRAS HRAS FGFBP1 EGFR CTNNB1
18 thymus development GO:0048538 9.67 CTNNB1 BRAF ATM
19 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 EGFR
20 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.64 FGFBP1 CTNNB1
21 meiotic telomere clustering GO:0045141 9.63 MLH1 ATM
22 entry of bacterium into host cell GO:0035635 9.61 CTNNB1 CDH1
23 cellular response to gamma radiation GO:0071480 9.61 TP53 HRAS ATM
24 response to isolation stress GO:0035900 9.6 KRAS HRAS
25 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 VEGFA TP53
26 positive regulation of MAP kinase activity GO:0043406 9.56 VEGFA KRAS HRAS EGFR
27 negative regulation of apoptotic process GO:0043066 9.56 VEGFA TP53 PIM2 EGFR CTNNB1 CEACAM5
28 cellular response to indole-3-methanol GO:0071681 9.52 CTNNB1 CDH1
29 anterior/posterior axis specification GO:0009948 9.5 CTNNB1 CDX2 AURKA
30 positive regulation of gene expression GO:0010628 9.23 VEGFA TP53 MIR182 KRAS HRAS CTNNB1

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activity GO:0004674 9.77 PIM2 CDK8 BRAF AURKA ATM
2 ATP binding GO:0005524 9.76 TP53 PIM2 MLH1 EGFR CDK8 BRAF
3 kinase activity GO:0016301 9.73 PIM2 EGFR CDK8 BRAF AURKA ATM
4 protein-containing complex binding GO:0044877 9.72 KRAS HRAS EGFR BRAF ATM
5 nucleotide binding GO:0000166 9.61 PIM2 MLH1 KRAS HRAS EGFR CDK8
6 protein kinase activity GO:0004672 9.1 PIM2 EGFR CDK8 BRAF AURKA ATM

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....